[ Back to EurekAlert! ]

PUBLIC RELEASE DATE:
2-Jun-2014

[ | E-mail ] Share Share

Contact: Cody Mooneyhan
cmooneyhan@faseb.org
301-634-7104
Federation of American Societies for Experimental Biology
@fasebopa

Common cholesterol drug greatly alters inflammatory response to common cold

New research published in the Journal of Leukocyte Biology suggests that because of their anti-inflammatory properties, future studies should examine the effects of statins specifically on viral-induced asthma exacerbations

Cold season may be just behind us, but a new discovery may shed light on how this common condition triggers asthma attacks. In a new research report published in the June 2014 issue of the Journal of Leukocyte Biology, researchers show that in individuals with asthma, statins significantly reduce the in vitro inflammatory response of human monocytes to rhinovirus (RV), the cause of the common cold. Not only does this discovery suggest that statins could help prevent or reduce the severity of asthma symptoms resulting from colds, but may also open the doors to further research into novel ways of controlling asthma attacks.

"Our findings--that statins reduce rhinovirus-induced CXCL10 secretion from human monocytic cells--suggest that these frequently prescribed drugs may affect asthma exacerbations caused by the common cold in adults," said Lisa E. Wickert, Ph.D., a researcher involved in the work from the Department of Biomolecular Chemistry and Nutritional Sciences at the University of Wisconsin-Madison in Madison, Wisconsin. "We hope that these findings will provide motivation to study how statins not only affect asthma symptoms but more specifically viral-induced asthma exacerbations."

To make their discovery, the researchers isolated human blood monocytes and lung macrophages from patients with allergies and/or asthma and treated the cells with simvastatin, a commonly prescribed statin drug. The cells were then stimulated with three different human RV strains. Researchers compared the inflammatory response of control-treated versus simvastatin-treated cells to RV by measuring CXCL10 secretion, an implicated therapeutic target for virus-induced asthma exacerbations. They found that CXCL10 secretion was lower from simvastatin-treated monocytic cells than in control-treated monocytic cells. In individuals with asthma, statins may modulate the immune response to rhinovirus, which can potentially affect the risk of a viral-induced asthma exacerbation.

"Not only does this report shed light on how colds exacerbate asthma, it also suggests new pathways and existing drugs that might be exploited to limit this, in some cases, severe combination of respiratory events," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology, "These findings also highlight an emerging appreciation for the interaction between metabolic pathways and the immune system."

###

The Journal of Leukocyte Biology publishes peer-reviewed manuscripts on original investigations focusing on the cellular and molecular biology of leukocytes and on the origins, the developmental biology, biochemistry and functions of granulocytes, lymphocytes, mononuclear phagocytes and other cells involved in host defense and inflammation. The Journal of Leukocyte Biology is published by the Society for Leukocyte Biology.

Details: Lisa E. Wickert, Maya R. Karta, Anjon Audhya, James E. Gern, and Paul J. Bertics. Simvastatin attenuates rhinovirus-induced interferon and CXCL10 secretion from monocytic cells in vitro. J. Leukoc. Biol. June 2014, 95:951-959; doi:10.1189/jlb.0713413 ; http://www.jleukbio.org/content/95/6/951.abstract



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.